GRPH

Graphite Bio, Inc.

3.04 USD
+0.04 (+1.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Graphite Bio, Inc. stock is down -0.98% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 February’s closed higher than January.

About Graphite Bio, Inc.

Graphite Bio, Inc. engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression. GPH201 is a product candidate for the treatment of X-linked severe combined immunodeficiency syndrome.